Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 7/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | APAF1 | O14727 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22925831 | 1.00 | HDAC4 (0.49) | HDAC4MAPTKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL20124833 | 0.81 | MAPT (0.47) | HDAC4MAPTKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL29620920 | 0.81 | HDAC4 (0.49) | HDAC4MAPTKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL12498160 | 0.81 | HDAC4 (0.46) | HDAC4MAPTKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL22925947 | 0.81 | HDAC4 (0.49) | HDAC4MAPTKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL26422895 | 0.79 | HDAC4 (0.46) | HDAC4MAPTKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL28987739 | 0.78 | PRKCI (0.38) | MAPTKDM4EALDH1A1TDP1HPGD | |
| SCHEMBL5130095 | 0.78 | MEN1 (0.50) | MAPTKDM4ESMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL22925738 | 0.76 | HDAC4 (0.40) | HDAC4MAPTKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL29620894 | 0.76 | HDAC4 (0.40) | HDAC4MAPTKDM4ESMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12152018-B2 | Compounds and compositions for treating conditions associated with STING activity | IFM DUE, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| CN-114450281-B | Inhibitor compounds | 辛塞拉治疗私人有限公司 | 2024-08-16 | — | — | CN | disclosed |
| CN-117529475-A | Heterobicyclic compounds containing urea or analogs for the treatment of diseases associated with STING activity and compounds thereof | 艾福姆德尤股份有限公司 | 2024-02-06 | — | — | CN | disclosed |
| EP-4274824-A1 | HETEROBICYCLIC COMPOUNDS HAVING AN UREA OR ANALOGUE AND THEIR COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM Due, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| CN-116261452-A | Compounds and compositions for the treatment of diseases associated with STING activity | 艾福姆德尤股份有限公司 | 2023-06-13 | — | — | CN | disclosed |
| EP-4182030-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM Due, Inc. (US) | 2023-05-24 | — | — | EP | disclosed |
| US-20220242852-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2022-08-04 | — | — | US | disclosed |
| EP-4003986-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2022-06-01 | — | — | EP | disclosed |
| CN-114450281-A | Inhibitor compounds | 辛塞拉治疗私人有限公司 | 2022-05-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220242852-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | HDAC4 2534/4885MAPT 3027/4885KDM4E 3761/4885 |
| US-12152018-B2 | Compounds and compositions for treating conditions associated with STING activity | STING1, CGAS, IRF3 | HDAC4 2759/4885MAPT 3201/4885KDM4E 3836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.